Filing Details

Accession Number:
0001725160-22-000068
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-04-05 18:52:55
Reporting Period:
2022-04-04
Accepted Time:
2022-04-05 18:52:55
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1725160 Zentalis Pharmaceuticals Inc. ZNTL () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1377952 Y Anthony Sun C/O Zentalis Pharmaceuticals, Inc.
1359 Broadway, Suite 1710
New York NY 10018
President & Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2022-04-04 10,471 $48.50 1,186,060 No 4 S Direct
Common Stock Disposition 2022-04-05 7,971 $51.34 1,178,089 No 4 S Direct
Common Stock Disposition 2022-04-05 2,500 $52.11 1,175,589 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 103,650 Indirect By Spouse
Common Stock 974,302 Indirect By Essex Group International, LLC
Common Stock 213,600 Indirect By Hao Bao Zi Trust LLC
Common Stock 125,000 Indirect By Hao Jiao Zi Trust LLC
Footnotes
  1. The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2021.
  2. The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $50.84 to $51.83. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $51.85 to $52.70. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. Represents shares nominally held by Hao Bao Zi Trust LLC on behalf of the Hao Bao Zi Trust (the "Trust"), the sole member of Hao Bao Zi Trust LLC. The Reporting Person's spouse is the investment adviser with sole power to make investment decisions regarding the securities held by the Trust. The Reporting Person disclaims beneficial ownership of the securities held by Hao Bao Zi Trust LLC except to the extent of his pecuniary interest therein, if any.
  5. Represents shares nominally held by Hao Jiao Zi Trust LLC on behalf of the Hao Jiao Zi Trust (the "Trust"), the sole member of Hao Jiao Zi Trust LLC. The Reporting Person's spouse is the investment adviser with sole power to make investment decisions regarding the securities held by the Trust. The Reporting Person disclaims beneficial ownership of the securities held by Hao Jiao Zi Trust LLC except to the extent of his pecuniary interest therein, if any.